NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more

Location: Gooimeer 2-35, Naarden, 1411 DC, Netherlands | Website: https://www.newamsterdampharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.085B

52 Wk Range

$14.06 - $27.29

Previous Close

$18.57

Open

$18.46

Volume

1,152,089

Day Range

$18.06 - $18.70

Enterprise Value

1.277B

Cash

808.5M

Avg Qtr Burn

-35.11M

Insider Ownership

0.39%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.